Kelly Magnuson is a senior leader with more than 20 years’ experience in the pharmaceutical, biotech, and medical device sectors. Ms. Magnuson joined Kura in 2017 as Vice President, Clinical Operations. Prior to her current role, Ms. Magnuson served as Vice President of Program Leadership at Aegerion Pharmaceuticals where she led the design and execution of the global commercial strategies for the rare disease products Juxtapid and Myalept. Previously, she was Vice President, Strategic Initiatives, Operational Excellence, and Communications at Integra LifeSciences; Vice President, Strategic Planning, and Portfolio Management for the Human Genetic Therapies Division at Shire Pharmaceuticals; and Portfolio Director for the Oncology Business Unit of Pfizer Pharmaceuticals. During her career, she has also designed and delivered project management training and certification courses within the industry and in academia. Ms. Magnuson holds an MBA from Rensselaer Polytechnic Institute, a Master of Science Degree in Microbiology from the University of Illinois, a Bachelor of Science Degree in Science Education from the University of Minnesota, and is a certified Project Management Professional.